

# CITATION REPORT

List of articles citing

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

DOI: 10.1111/apt.12869

Alimentary Pharmacology and Therapeutics, 2014, 40, 620-8.

**Source:** <https://exaly.com/paper-pdf/58179955/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
150	Editorial: drug monitoring targets for optimising adalimumab in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 854-5	6.1	2
149	Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. <b>2014</b> , 12, 76-89		3
148	How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 11331-42	5.6	3
147	Current stage in inflammatory bowel disease: What is next?. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 11282-303	5.6	15
146	Optimizing the use of biological therapy in patients with inflammatory bowel disease. <b>2015</b> , 3, 63-8		50
145	Safety considerations when using anti-TNF therapy to treat Crohn's disease. <b>2015</b> , 14, 31-44		7
144	Anti-tumor necrosis factor therapy in uveitis. <b>2015</b> , 60, 575-89		65
143	Therapeutic drug monitoring of anti-TNF agents in inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , <b>2015</b> , 15, 1107-17	5.4	11
142	[Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?]. <b>2015</b> , 74, 689-94		
141	Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , <b>2016</b> , 50, 483-9	3	17
140	Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 409-15	4.5	81
139	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1999-2015	4.5	71
138	How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 998-1009	4.5	15
137	Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. <b>2016</b> , 16, 82		3
136	A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 2289-301	4.5	27
135	[Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease]. <b>2016</b> , 39, 265-72		2
134	Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. <b>2016</b> , 125, 62-7		28

133	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. <b>2016</b> , 51, 1081-6		26
132	Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease. <b>2016</b> , 39, 265-272		
131	Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1302-9	6.9	27
130	Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2016</b> , 9, 513-26	4.7	46
129	Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 30-51	6.1	171
128	The Role of Laboratory Tests in Crohn's Disease. <b>2016</b> , 9, 51-62		14
127	Emerging issues in the medical management of Crohn's disease. <b>2016</b> , 32, 103-9		4
126	Treat to Target in Inflammatory Bowel Disease. <b>2016</b> , 14, 61-72		26
125	Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 543-9	6.9	123
124	Use of anti-TNF drug levels to optimise patient management. <b>2016</b> , 7, 289-300		64
123	Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. <b>2016</b> , 7, e135		285
122	Optimizing Anti-TNF Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 550-557.e2	6.9	239
121	Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1359-1372.e6	6.9	34
120	Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1135-1145	6.1	29
119	Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 923-932	6.1	22
118	Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 339-343	3.2	9
117	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 150-161	6.1	46
116	Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases. <b>2017</b> , 49, 947-956		23

115	Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 322-326	3.2	18
114	Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1047-1056	4.5	11
113	Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. <b>2017</b> , 34, 1556-1563		10
112	Therapeutic drug monitoring of anti-tumour necrosis factor- $\alpha$ agents in inflammatory bowel disease. <b>2017</b> , 16, 303-317		17
111	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 1037-1053	6.1	165
110	Pharmacokinetics of Therapeutic Proteins. <b>2017</b> , 311-340		1
109	Update on Therapeutic Drug Monitoring in Crohn's Disease. <b>2017</b> , 46, 645-659		6
108	Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 873-882	6.1	50
107	Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1454-1460	4.5	16
106	American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. <b>2017</b> , 153, 835-857.e6		162
105	American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. <b>2017</b> , 153, 827-834		295
104	Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis. <b>2017</b> , 7, e014581		9
103	Tricks of the Trade: Treating Your Patient with Moderate-to-Severe IBD. <b>2017</b> , 147-182		
102	Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy. <b>2017</b> , 52, 204-208		8
101	Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies?. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 76-78	6.9	
100	Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. <b>2017</b> , 152, 351-361.e5		153
99	Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 276-282	6.1	75
98	Can We Predict the Efficacy of Anti-TNF- $\alpha$ Agents?. <b>2017</b> , 18,		43

97	Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases. <b>2017</b> , 17, 97		12
96	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. <b>2018</b> , 57, 1075-1106		10
95	Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?. <b>2018</b> , 58, 864-876		13
94	Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 1531-1538	4.5	27
93	Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2018</b> , 11, 1756284818759930	4.7	10
92	Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 896-905	6.1	74
91	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 653-661	1.5	18
90	Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. <b>2018</b> , 154, 1660-1671		108
89	A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 24, 191-197	4.5	22
88	A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. <b>2018</b> , 53, 670-676		19
87	Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease. <b>2018</b> , 10, 592-596		20
86	Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. <b>2018</b> , 17, 185-196		10
85	Adalimumab trough levels predict Crohn's disease clinical course. <b>2018</b> , 50, 204-206		3
84	Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 1271-1279	5.4	10
83	Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2018</b> , 67, 257-291	2.8	145
82	Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 333-339	6.1	10
81	How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. <b>2018</b> , 12, 797-810		23
80	Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 3067-3073	4	40

79	Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 731-739	6.1	41
78	Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 890-898	0.7	41
77	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. <b>2019</b> , 17, 285-310		41
76	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. <b>2019</b> , 54, 1220-1225		4
75	Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. <b>2019</b> , 17, 127-145		23
74	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1655-1668.e3	6.9	116
73	Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits. <b>2019</b> , 57, 1906-1914		11
72	Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 1527-1536	1.5	2
71	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Biologics. <b>2019</b> , 243-255		0
70	Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease. <b>2019</b> , 19, 547-555		2
69	Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment?. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 907-918	5.4	5
68	Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). <i>Journal of Gastroenterology</i> , <b>2019</b> , 54, 860-870	6.9	14
67	Key insights from therapeutic drug monitoring in Crohn's disease patients. <b>2019</b> , 15, 399-406		8
66	Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. <b>2019</b> , 39, 841-849		8
65	Accuracy of the new rapid test for monitoring adalimumab levels. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819828238	4.7	9
64	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. <b>2019</b> , 34, 1296-1315		18
63	Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 1248-1256	1.5	26
62	A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease. <b>2019</b> , 1067, 63-70		27

61	Infliximab therapy intensification upon loss of response: Is there an optimal trough level?. <b>2019</b> , 51, 1106-11116		
60	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1357-1366	4.5	3
59	Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study. <b>2019</b> , 38, 44-54		17
58	Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1036-1043	4.5	15
57	Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. <b>2019</b> , 11, 178-190		7
56	Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease. <b>2020</b> , 8, 167-174		5
55	Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 185-191	1.5	7
54	Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease. <b>2020</b> , 4, 410-416		2
53	Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. <b>2020</b> , 12, e10919		24
52	Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 1627-1635	4.5	14
51	Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 289-294	3.2	7
50	Biological therapy in pediatric age. <i>Pharmacological Research</i> , <b>2020</b> , 161, 105120	10.2	3
49	Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1346-1355	4.5	5
48	Design and Evaluation of a Multiplexed Assay to Assess Human Immunogenicity Against Humira®. <i>AAPS Journal</i> , <b>2020</b> , 22, 104	3.7	1
47	Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
46	Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1443-1451	4.5	6
45	Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 1354-1363	1.5	19
44	The shining DIAMOND for evidence-based treatment strategies for Crohn's disease. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 824-832	6.9	0

43	Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 612-628	6.1	22
42	Infliximab levels and antibodies in IBD-related peripheral arthralgia. <i>International Journal of Colorectal Disease</i> , <b>2020</b> , 35, 1141-1148	3	4
41	Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series. <i>American Journal of Clinical Dermatology</i> , <b>2021</b> , 22, 275-283	7.1	3
40	Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. <i>BioDrugs</i> , <b>2021</b> , 35, 35-45	7.9	0
39	Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2261, 291-306	1.4	1
38	Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2021</b> , 72, 870-876	2.8	1
37	Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 610806	5.6	6
36	Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-antagonists. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 539-548	5.4	3
35	Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. <i>EBioMedicine</i> , <b>2021</b> , 66, 103329	8.8	1
34	Advances in the Comprehensive Management of Postoperative Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	5
33	Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. <i>Crohn's &amp; Colitis 360</i> , <b>2021</b> , 3,	1.4	0
32	Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease. <i>Frontiers in Pediatrics</i> , <b>2021</b> , 9, 646671	3.4	0
31	Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 249-266	6.1	2
30	Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review. <i>Health Technology Assessment</i> , <b>2021</b> , 25, 1-66	4.4	1
29	Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study. <i>Digestion</i> , <b>2021</b> , 102, 929-937	3.6	0
28	Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease. <i>PLoS ONE</i> , <b>2021</b> , 16, e0254548	3.7	0
27	Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 645-651	3.2	2
26	Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-Inhibitors?. <i>American Journal of Clinical Dermatology</i> , <b>2021</b> , 22, 139-147	7.1	4



25	Aktualisierte S3-Leitlinie Colitis ulcerosa [Living Guideline. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2020</b> , 58, e241-e326	1.6	6
24	Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 821-828	3.2	2
23	Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF- $\alpha$ ) inhibitors [LISA-TRACKER $\square$ enzyme-linked immunosorbent assay (ELISA) kits, TNF-Blocker ELISA kits and Promonitor $\square$ ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. <i>Health Technology Assessment</i> , <b>2016</b> , 20, 1-288	4.4	17
22	Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients. <i>Journal of Korean Medical Science</i> , <b>2020</b> , 35, e114	4.7	5
21	Disease monitoring strategies in inflammatory bowel diseases: What do we mean by "tight control"?. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 6172-6189	5.6	12
20	Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , <b>2017</b> , 8, 155-161	3	13
19	What Is the Best Possible Therapy for My Crohn's Disease? State-of-the-Art Therapy for Newly Diagnosed Crohn's Disease. <b>2015</b> , 59-71		
18	Is there a beneficial effect of adding azathioprine to adalimumab in Crohn's disease patients?. <i>Annals of Translational Medicine</i> , <b>2018</b> , 6, 278	3.2	2
17	DIAMOND study: an additional evidence of the interest of being proactive in IBD. <i>Annals of Translational Medicine</i> , <b>2018</b> , 6, 279	3.2	
16	Azathioprine with Allopurinol Is a Promising First-Line Therapy for Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	3
15	Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , <b>2014</b> , 10, 478-489	0.7	1
14	Medical Therapy for Crohn's Disease. <b>2022</b> , 781-798		
13	Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> , 55, 810-814	3	0
12	Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2022</b> , 15, 17562848211068659	4.7	0
11	Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease, a Retrospective Cohort Study.. <i>American Journal of Gastroenterology</i> , <b>2022</b> , 117,	0.7	0
10	Pharmacokinetic and clinical monitoring through posologic change in adalimumab intensification regimen from 40 mg every week to 80 mg every other week.. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2022</b> ,	0.9	
9	Comparison of Timing to Develop Anti-Drug Antibodies to Infliximab and Adalimumab Between Adult and Pediatric Age Groups, Males and Females.. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , <b>2022</b> , 27, 63-71	1.6	0
8	Adalimumab in Pediatric Inflammatory Bowel Disease.. <i>Frontiers in Pediatrics</i> , <b>2022</b> , 10, 852580	3.4	1

- 7 The IBD Management Puzzle: Do We Have All the Pieces?. 18-26
- 6 The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease. **2022**, 13, 53-58
- 5 Therapie des Morbus Crohn und der Colitis ulcerosa. **2023**, 131-151
- 4 Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial. **2023**,
- 3 The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn's Disease or Ulcerative Colitis. 84-93
- 2 Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn's Disease: A Cross-Sectional Multicentric Latin American Study. **2023**, 15, 586
- 1 Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease. **2023**, 12, 2452